This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Cyramza
  • /
  • A Study of Ramucirumab (LY3009806) in Combination ...
Clinical trial

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Read time: 1 mins
Last updated:25th Aug 2021
Status: COMPLETED
Identifier: NCT02314117
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)


ClinicalTrials.gov ID: NCT02314117

Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company (Responsible Party)
Last Update Posted: 2021-08-26

Brief Summary:
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.

Official Title:
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)

Intervention / Treatment:
- Drug: Ramucirumab
- Drug: Capecitabine
- Drug: Cisplatin
- Drug: Placebo
- Drug: Fluorouracil

Category Value
Study Start (Actual) 2015-01-20
Primary Completion (Estimated) 2017-01-17
Study Completion (Estimated) 2020-08-14
Enrollment (Estimated) 645
Study Type Interventional
Phase Phase 3
Other Study ID Numbers
15372

I4T-MC-JVCU (Other Identifier) (OTHER: Eli Lilly and Company)

2014-002240-40 (EudraCT Number)


View full details